Table 4.
Mean change from baseline in BCVA at 6 months
| Outcome of interest | Studies (n) | WMD (95% CI) | P | Study heterogeneity | ||
|---|---|---|---|---|---|---|
| χ2 | P | I 2 | ||||
| IVR 0.5 mg vs non-anti-VEGF | ||||||
| Type of RVO | ||||||
| All trials | 4 | 12.30 (10.03,14.58) | <0.001 | 1.66 | 0.646 | 0.00% |
| CRVO | 2 | 14.05 (10.54, 17.56) | <0.001 | 0.02 | 0.900 | 0.00% |
| BRVO | 2 | 11.05 (8.07, 14.02) | <0.001 | 0.01 | 0.933 | 0.00% |
| Sample size | ||||||
| All trials | 4 | 12.30 (10.03,14.58) | <0.001 | 1.66 | 0.646 | 0.00% |
| >100 | 2 | 12.43 (9.40, 15.46) | <0.001 | 1.61 | 0.205 | 37.9% |
| <100 | 2 | 11.74 (3.98, 19.51) | <0.001 | 0.03 | 0.868 | 0.00% |
| Different non-anti-VEGF treatment | ||||||
| All trials | 4 | 12.30 (10.03,14.58) | <0.001 | 1.66 | 0.646 | 0.00% |
| Sham | 3 | 12.37 (10.02, 14.72) | <0.001 | 1.62 | 0.446 | 0.00% |
| Sham plus laser | 1 | 11.40 (2.64, 20.16) | 0.011 | - | ||
| IVR 0.5 mg vs IVR 0.3 mg | 2 | 1.90 (−0.35, 4.16) | 0.098 | 0.05 | 0.831 | 0.00% |
| IVR 0.3 mg vs non-anti-VEGF | 2 | 10.26 (7.80, 12.72) | <0.001 | 1.11 | 0.293 | 9.50% |
BCVA = best-corrected visual acuity; WMD = weighted mean differences; OR = odds ratio; CI = confidence interval; IVR = intravitreal ranibizumab; VEGF = vascular endothelial growth factor; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion; BRVO = branch retinal vein occlusion.